Key Takeaways for Pfizer Stock’s Dividend as of July 2026
- Revenue for the quarter ended March 29, 2026 came in at $14.45 billion, up 5% year over year, but operating income fell 5% over the same stretch to $4.57 billion.
- Pfizer held its quarterly dividend at $0.43 per share for the period ended March 31, 2026, matching the $0.43 paid the quarter before.
- That $0.43 figure has now repeated across four straight reported quarters, and Pfizer stock trades at $24, sitting far closer to its 52-week low of $23.11 than its high of $29.
- TIKR’s mid-case model puts a $28 target on Pfizer stock, realized by December 2030, for a 14% total return and a 3% annualized rate.
Pfizer Stock’s Latest Quarter Shows Revenue Growth Outpacing Operating Income
Pfizer (PFE) reported $14.45 billion in total revenue for the quarter ended March 29, 2026, up 5% from the $13.72 billion posted a year earlier. That top-line gain didn’t carry through the rest of the income statement.
Gross profit came in at $11.04 billion, a 76% margin, roughly in line with the 81% margin posted in the year-ago period. Operating income told a different story.
Operating income fell to $4.57 billion, down 5% year over year and well off the $4.82 billion reported in the quarter ended March 30, 2025. The operating margin landed at 32%, compared with 35% a year prior.
Revenue is moving in the right direction. The line that funds shareholder payouts is not moving with it, and that tension sits underneath everything Pfizer stock’s dividend record shows next.
PFE Stock’s Yield Looks Wide Against a Range Near Its 52-Week Low
Pfizer paid $0.43 per share for the quarter ended March 31, 2026, identical to the $0.43 paid the quarter before. The figure hasn’t changed since at least June 2025.
Accordingly, that $0.43 rate has now held for four consecutive reported quarters: June 2025, September 2025, December 2025, and March 2026. Estimates carry it forward unchanged through December 2026 before a step to $0.44 projected for the quarter ending March 2027.
Against that flat record, the NTM dividend yield sits at 7.1% as of July 2, 2026, up from 6.5% just three months earlier at the end of March. Pfizer stock trades at $24, well below its 52-week high of $29 and just above its low of $23.
A yield that widened from 6.5% to 7.1% in a single quarter did so because the price slid toward its 52-week floor, not because the payout grew. That’s the mechanism behind the number, and it changes how the 7% figure should be read.
Whether that yield holds near 7% or compresses depends entirely on where Pfizer stock sits relative to its $23 low in the quarters ahead.
TIKR’s $28 Target on PFE Stock Holds if the Payout Stays at $0.43
TIKR’s mid-case model puts Pfizer stock’s target price at $28, realized by December 2030, for a potential total return of 14% and an annualized rate of 3% from the current $24 share price.
A 3% annualized return sitting mostly on a 7% yield rather than price appreciation positions Pfizer stock as an income holding first, with the model pricing in limited multiple expansion between now and 2030.
That framing lines up with what the quarter showed. Revenue grew 5.4% while operating income slipped 5.3%, and a dividend held flat for four straight quarters reflects a company protecting the payout rather than pushing it higher while that gap persists.
Should You Invest in Pfizer Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Pfizer Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Pfizer Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze PFE stock on TIKR for Free →
